practical or commercial use in animal and/or human health, agriculture or as biochemical reagents (for example, pepsatin and staurosporine). Until recently, much of the material published was from the results of Japanese research work. It is now envisaged that, following the link with NPG, arguably the world's leader in science publishing, JA will adopt a truly global mantle, with an ever-increasing number of international contributors and readers. We specifically intend to place JA firmly in the vanguard of research publications focusing on antibiotics.
No journal can establish itself and thrive without the unswerving commitment and drive of talented and dedicated individuals. JA was fortunate in having such a man in the long-serving JARA Managing Director, the late Dr Yukimasa Yagaisawa, who expertly assumed and carried out the post and duties of Managing Editor of the journal. He, along with Dr Morimasa Yagisawa, was responsible for setting up and maintaining the journal's highly effective publication and administrative systems. The current Editorial Board members, journal staff and I will strive to build on their solid foundation and propel the journal to new levels of excellence and impact.
I would like to take this opportunity to express my immense gratitude to all those associated with JA, including researchers, readers, authors and all those involved in the various aspects of production and operation, for their support and encouragement through the years. In particular, I would like to reaffirm my sincere thanks to the many Friends of the Journal who have provided financial resources and support in recognition of the import and significance of the publication, and I hope that we can count on continued and increasing support in the foreseeable future. I humbly invite all to join me and my colleagues-at JA and at NPG-in an exciting journey to elevate the journal to greater heights in a new era of innovative research and development that will hopefully provide us all with new knowledge, better understanding, and new and novel antibiotics that are so desperately needed.
